ClinicalTrials.gg
WithdrawnNCT00386555Updated Aug 9, 2012

A Phase 2 Study in Patients With Advanced Non-Small Cell Lung Cancer Using New Agents With and Without Docetaxel.

A Phase 2 interventional study of docetaxel and CP-868,596 + docetaxel in Carcinoma, Non-Small-Cell Lung, sponsored by Arog Pharmaceuticals, Inc.. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-08-09.

Sponsored by Arog Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Study was cancelled before patient enrollment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 198 studies testing docetaxel in Carcinoma, Non-Small-Cell Lung — 13 open to participants now, 20 under way, 3 of them phase 3. Docetaxel · Carcinoma, Non-Small-Cell Lung.

Enrollment
182nd of 188
0 · median 50
Started
2007
with 14 others
Phase 2
125 of 198
9 open now
Registered
77th of 198
by date

Among the 198 studies testing docetaxel in Carcinoma, Non-Small-Cell Lung, this one is the 182nd largest by enrollment of the 188 interventional ones that give a count, is one of 15 that started in 2007, is one of 125 in phase 2, and was the 77th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

13 of the 198 studies testing docetaxel in Carcinoma, Non-Small-Cell Lung are open now, in 8 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About docetaxel

Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing docetaxel in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

To determine the effectiveness of CP-868,596 + docetaxel, AG-013736 + docetaxel and CP-868,596 + AG-013736 + docetaxel in patients previously treated for non-small cell lung cancer.

03

Conditions studied

  • Carcinoma, Non-Small-Cell Lung
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Platinum-pretreated patients with advanced stage IIIb or IV NSCLC

Exclusion criteria

Exclusion Criteria:

  • Centrally-located tumors
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Interventions

  • DrugCP-868,596 + docetaxel
  • DrugAG-013736 + docetaxel

    Drug pages: Axitinib · Docetaxel

  • DrugCP-868,596 + AG-013736 + docetaxel
06

What researchers measure

Primary outcomes

  1. Determine the anti-tumor efficacy of CP 868,596 plus docetaxel, AG 013736 plus docetaxel, CP 868,596 plus AG 013736 plus docetaxel, and docetaxel alone in patients with advanced NSCLC based on objective tumor response (CR and PR) rate

Secondary outcomes

  1. Determine the safety and tolerability of the combination of daily CP 868,596 and docetaxel on an every 3 week schedule

  2. Determine the safety and tolerability of the combination of daily AG 013736 and docetaxel on an every 3 week schedule

  3. Determine the safety and tolerability of both CP 868,596 and AG 013736 given together with docetaxel on an every 3 week schedule

  4. Assess additional evidence of anti-tumor activity as measured by duration of objective response, progression-free survival, and one-year survival (OS1year)

  5. Evaluate the pharmacokinetics (PK) of AG 013736 and CP 868,596 when given together with and without docetaxel

  6. Evaluate the PK of CP 868,596 when given in combination with docetaxel

  7. Evaluate the PK of docetaxel when given in combination with CP 868,596, or CP 868,596 plus AG 01373

07

Study locations

No study locations are listed for this record.

08

References and documents

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 9, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00386555
Lead sponsor
Arog Pharmaceuticals, Inc.
First posted
Oct 11, 2006
Start date
May 2007
Last update
Aug 9, 2012

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in May 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Docetaxel · Axitinib

Start the discussion